For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.
The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.
read more